Nephrocare Health Services Limited (NEPHROPLUS)
Outcome of Board Meeting
Q1FY27 results (unaudited):
Standalone:
Revenue 1.7bn +14% y-y (1.5bn)
PAT 0.13bn +150% y-y (0.05bn)
Consolidated:
Revenue 2.8bn +24% y-y (2.3bn)
PAT 0.32bn +35% y-y (0.24bn)
FY26 results (audited):
Standalone:
Revenue 6.3bn
PAT (loss) -0.08bn
Consolidated:
Revenue 10.0bn
PAT 0.77bn
Commentary: The quarter includes initial accounting for seven asset transfer arrangements with provisional purchase consideration allocation; the Group also incorporated a new wholly owned subsidiary in Kazakhstan to expand operations.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 NEPHROPLUS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add NEPHROPLUS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Nephrocare Health Services Limited
Important.
The summary above is generated automatically from Nephrocare Health Services Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.